Greenleaf Trust’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.17M | Buy |
6,371
+62
| +1% | +$11.4K | 0.01% | 298 |
|
|
2025
Q4 | $1.11M | Buy |
6,309
+190
| +3% | +$31K | 0.01% | 306 |
|
|
2025
Q3 | $857K | Buy |
6,119
+450
| +8% | +$60.8K | 0.01% | 366 |
|
|
2025
Q2 | $712K | Buy |
5,669
+2,714
| +92% | +$338K | 0.01% | 406 |
|
|
2025
Q1 | $404K | Sell |
2,955
-2,110
| -42% | -$302K | ﹤0.01% | 555 |
|
|
2024
Q4 | $775K | Buy |
5,065
+2,459
| +94% | +$415K | 0.01% | 397 |
|
|
2024
Q3 | $505K | Sell |
2,606
-3,475
| -57% | -$727K | ﹤0.01% | 512 |
|
|
2024
Q2 | $1.41M | Buy |
6,081
+4,610
| +313% | +$1M | 0.01% | 236 |
|
|
2024
Q1 | $317K | Sell |
1,471
-684
| -32% | -$160K | ﹤0.01% | 588 |
|
|
2023
Q4 | $558K | Buy |
2,155
+365
| +20% | +$89.7K | 0.01% | 426 |
|
|
2023
Q3 | $460K | Buy |
1,790
+171
| +11% | +$45.7K | 0.01% | 460 |
|
|
2023
Q2 | $461K | Buy |
1,619
+19
| +1% | +$5.66K | ﹤0.01% | 470 |
|
|
2023
Q1 | $445K | Sell |
1,600
-244
| -13% | -$67.5K | 0.01% | 487 |
|
|
2022
Q4 | $511K | Buy |
1,844
+719
| +64% | +$203K | 0.01% | 440 |
|
|
2022
Q3 | $300K | Sell |
1,125
-1
| -0.1% | -$212 | ﹤0.01% | 535 |
|
|
2022
Q2 | $230K | Sell |
1,126
-602
| -35% | -$123K | ﹤0.01% | 638 |
|
|
2022
Q1 | $364K | Sell |
1,728
-159
| -8% | -$34.6K | ﹤0.01% | 519 |
|
|
2021
Q4 | $453K | Sell |
1,887
-1,514
| -45% | -$389K | 0.01% | 444 |
|
|
2021
Q3 | $962K | Buy |
3,401
+1,298
| +62% | +$425K | 0.01% | 239 |
|
|
2021
Q2 | $728K | Sell |
2,103
-182
| -8% | -$55.1K | 0.01% | 302 |
|
|
2021
Q1 | $639K | Buy |
2,285
+532
| +30% | +$143K | 0.01% | 311 |
|
|
2020
Q4 | $429K | Sell |
1,753
-522
| -23% | -$135K | 0.01% | 377 |
|
|
2020
Q3 | $645K | Buy |
2,275
+364
| +19% | +$102K | 0.01% | 237 |
|
|
2020
Q2 | $511K | Sell |
1,911
-217
| -10% | -$65.2K | 0.01% | 267 |
|
|
2020
Q1 | $673K | Buy |
2,128
+517
| +32% | +$157K | 0.01% | 178 |
|
|
2019
Q4 | $478K | Buy |
1,611
+22
| +1% | +$6.1K | 0.01% | 301 |
|
|
2019
Q3 | $370K | Sell |
1,589
-721
| -31% | -$168K | 0.01% | 355 |
|
|
2019
Q2 | $540K | Buy |
2,310
+406
| +21% | +$93.7K | 0.01% | 270 |
|
|
2019
Q1 | $450K | Sell |
1,904
-655
| -26% | -$206K | 0.01% | 285 |
|
|
2018
Q4 | $770K | Buy |
2,559
+115
| +5% | +$36.7K | 0.02% | 187 |
|
|
2018
Q3 | $863K | Buy |
2,444
+980
| +67% | +$337K | 0.02% | 193 |
|
|
2018
Q2 | $425K | Buy |
1,464
+637
| +77% | +$179K | 0.01% | 310 |
|
|
2018
Q1 | $226K | Sell |
827
-80
| -9% | -$24.8K | ﹤0.01% | 404 |
|
|
2017
Q4 | $289K | Buy |
907
+76
| +9% | +$24.4K | 0.01% | 343 |
|
|
2017
Q3 | $260K | Buy |
+831
| New | +$246K | 0.01% | 341 |
|
Other funds holding BIIB
VCM
VPM
Greenleaf Trust's BIIB Position: Q1 2026 in Review
Greenleaf Trust increased its Biogen (BIIB) stake by 0.98% in Q1 2026, buying an estimated $11.4K and bringing the position to 6,371 shares worth $1.17M. The position accounts for 0.01% of the portfolio, ranked #298.
Greenleaf Trust first reported a position in BIIB in Q3 2017 and has held it in 35 quarters since. The position peaked at $1.41M in Q2 2024. 1,002 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.
- Greenleaf Trust held 6,371 shares of Biogen worth $1.17M as of Q1 2026.
- Greenleaf Trust bought 62 Biogen shares in Q1 2026, an estimated $11.4K.
- Biogen made up 0.01% of Greenleaf Trust's portfolio in Q1 2026, its #298 holding.
- Greenleaf Trust first reported a position in Biogen in Q3 2017 and has held it in 35 quarters since.
- Greenleaf Trust's Biogen position peaked at $1.41M in Q2 2024.
- 1,002 funds tracked by Wall St. Rank held Biogen as of Q1 2026.
Based on Greenleaf Trust's 13F filing for Q1 2026, filed 27 Apr 2026.